Citadel Advisors
TTRX

Citadel Advisors’s Turn Therapeutics TTRX Stock Holding History

Citadel Advisors’s Portfolio TTRX Stock Details TTRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$189K Buy
+25,874
New +$120K ﹤0.01% 12131
2026
Q1 		– Sell
-20,986
Closed -$82.7K – 14807
2025
Q4 		$82.7K Buy
+20,986
New +$87.5K ﹤0.01% 11782

Other funds holding TTRX

SW
SteelPeak Wealth Woodland Hills, California $3.86B AUM 48.92% 1-Year Est. Return
IC
IEQ Capital Foster City, California $21.7B AUM 77.3% 1-Year Est. Return
DI
DDFG Inc Thousand Oaks, California $504M AUM 18.61% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
WSC
Wellington Shields & Co New York $446M AUM 38.92% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BA
Bridgewater Advisors New York $1.83B AUM 22.9% 1-Year Est. Return
AWA
Aaron Wealth Advisors Chicago, Illinois $1.97B AUM 36.91% 1-Year Est. Return
TS
Tamar Securities Woodland Hills, California $1.07B AUM 26.86% 1-Year Est. Return

Citadel Advisors's TTRX Position: Q2 2026 in Review

Citadel Advisors opened a new position in Turn Therapeutics (TTRX) in Q2 2026: 25,874 shares worth $189K. The stake represents ﹤0.01% of the portfolio and ranks #12131 among its holdings. This is a return to the name: Citadel Advisors previously reported a position in TTRX as recently as Q4 2025.

Citadel Advisors first reported a position in TTRX in Q4 2025 and has held it in 2 quarters since. 29 funds tracked by Wall St. Rank hold TTRX as of Q2 2026.

  • Citadel Advisors held 25,874 shares of Turn Therapeutics worth $189K as of Q2 2026.
  • Turn Therapeutics was a new Citadel Advisors position in Q2 2026.
  • Turn Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #12131 holding.
  • Citadel Advisors first reported a position in Turn Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 29 funds tracked by Wall St. Rank held Turn Therapeutics as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.